Mayne Pharma Group Statistics
Want to see AU:MYX full AI Analyst Report?
Mayne Pharma Group (MYX) Stock Statistics & Valuation Metrics
Total Valuation
Mayne Pharma Group has a market cap or net worth of AUD 277.61M. The enterprise value is AUD 224.67M.
- Market Cap
- AUD 277.61M
- Enterprise Value
- AUD 224.67M
Share Statistics
Mayne Pharma Group has 81,890,884 shares outstanding. The number of shares has decreased by -2.65% in one year.
- Shares Outstanding
- 81,890,884
- Owned by Insiders
- 0.31%
- Owned by Institutions
- 6.88%
Financial Efficiency
Mayne Pharma Group’s return on equity (ROE) is 0.06 and return on invested capital (ROIC) is -4.33%.
- Return on Equity (ROE)
- 0.06
- Return on Assets (ROA)
- 0.03
- Return on Invested Capital (ROIC)
- -4.33%
- Return on Capital Employed (ROCE)
- -0.05
- Revenue Per Employee
- 1.06M
- Profits Per Employee
- 67.42K
- Employee Count
- 363
- Asset Turnover
- 0.42
- Inventory Turnover
- 3.45
Valuation Ratios
The current PE Ratio of Mayne Pharma Group is 10.65. Mayne Pharma Group’s PEG ratio is 0.07.
- PE Ratio
- 10.65
- PS Ratio
- 0.70
- PB Ratio
- 0.69
- Price to FCF
- 21.32
- Price to Operating Cash Flow
- 17.17
- PEG Ratio
- 0.07
Income Statement
In the last 12 months, Mayne Pharma Group had revenue of 383.68M and earned 24.47M in profits. Earnings per share was 0.31.
- Revenue
- 383.68M
- Gross Profit
- 192.21M
- Operating Income
- -34.28M
- Pretax Income
- 35.76M
- Net Income
- 24.47M
- EBITDA
- 29.40M
- Earnings Per Share (EPS)
- 0.31
Cash Flow
In the last 12 months, operating cash flow was 15.62M and capital expenditures -2.94M, giving a free cash flow of 12.67M billion.
- Operating Cash Flow
- 15.62M
- Free Cash Flow
- 12.67M
- Free Cash Flow per Share
- 0.16
Dividends & Yields
Mayne Pharma Group pays an annual dividend of AUD 0.54, resulting in a dividend yield of ―
- Dividend Per Share
- AUD 0.54
- Dividend Yield
- ―
- Payout Ratio
- N/A
- Free Cash Flow Yield
- 4.69%
- Earnings Yield
- 9.13%
Stock Price Statistics
- Beta
- 0.32
- 52-Week Price Change
- -31.96%
- 50-Day Moving Average
- 2.81
- 200-Day Moving Average
- 2.67
- Relative Strength Index (RSI)
- 68.70
- Average Volume (3m)
- 233.75K
Important Dates
Mayne Pharma Group upcoming earnings date is Feb 24, 2027, TBA (Not Confirmed).
- Last Earnings Date
- Aug 26, 2026
- Next Earnings Date
- Feb 24, 2027
- Ex-Dividend Date
- Jan 18, 2023
Financial Position
Mayne Pharma Group as a current ratio of 1.31, with Debt / Equity ratio of 11.05%
- Current Ratio
- 1.31
- Quick Ratio
- 1.09
- Debt to Market Cap
- 0.19
- Net Debt to EBITDA
- -1.33
- Interest Coverage Ratio
- -6.46
Taxes
In the past 12 months, Mayne Pharma Group has paid 4.56M in taxes.
- Income Tax
- 4.56M
- Effective Tax Rate
- 0.13
Enterprise Valuation
Mayne Pharma Group EV to EBITDA ratio is 28.41, with an EV/FCF ratio of 18.24.
- EV to Sales
- 0.60
- EV to EBITDA
- 28.41
- EV to Free Cash Flow
- 18.24
- EV to Operating Cash Flow
- 14.80
Balance Sheet
Mayne Pharma Group has AUD 82.25M in cash and marketable securities with AUD 43.20M in debt, giving a net cash position of AUD 39.05M billion.
- Cash & Marketable Securities
- AUD 82.25M
- Total Debt
- AUD 43.20M
- Net Cash
- AUD 39.05M
- Net Cash Per Share
- AUD 0.48
- Tangible Book Value Per Share
- -AUD 0.89
Margins
Gross margin is 49.62%, with operating margin of -14.48%, and net profit margin of 6.38%.
- Gross Margin
- 49.62%
- Operating Margin
- -14.48%
- Pretax Margin
- 9.32%
- Net Profit Margin
- 6.38%
- EBITDA Margin
- 2.12%
- EBIT Margin
- -14.48%
Analyst Forecast
The average price target for Mayne Pharma Group is AUD 3.98, which is 11.43% higher than the current price. The consensus rating is Moderate Buy
- Price Target
- AUD 3.98
- Price Target Upside
- 20.45% Upside
- Analyst Consensus
- Moderate Buy
- Analyst Count
- 2
- Revenue Growth Forecast
- -5.98%
- EPS Growth Forecast
- ―
Scores
- Smart Score
- 8
- AI Score
- 60
